TOPCHOICE MEDICAL CORPORATION: Plans to Repurchase and Cancel Shares for Up to RMB 100 Million.

Source: Topchoice Medical's "Share Buyback Report on Repurchasing Company Shares via Centralized Competitive Bidding"

DentalGoodNews｜June 27, 2026 - TOPCHOICE MEDICAL CORPORATION (hereinafter referred to as "TOPCHOICE MEDICAL") officially released the "Share Repurchase Report on Repurchasing Company Shares via Centralized Auction Trading". The announcement shows that TOPCHOICE MEDICAL plans to use RMB 50 million (inclusive) to RMB 100 million (inclusive) of its own or self-raised funds to repurchase its issued A-shares through centralized auction trading, with the repurchase price cap set at RMB 60.12 per share.

According to previous reports by DENTALGOODNEWS (Leading Dental Industry Media, DGN), TOPCHOICE MEDICAL first disclosed this repurchase plan on June 4, 2026. The report released this time confirms that all repurchased shares will be used to reduce the company's registered capital, i.e., they will be cancelled after the repurchase is completed. Based on the repurchase price cap of RMB 60.12 per share, the estimated number of shares to be repurchased is approximately 831,700 to 1,663,300 shares, accounting for about 0.19% to 0.37% of the company's current total share capital.

In terms of funding sources, TOPCHOICE MEDICAL explicitly stated that it will use its own funds or self-raised funds. As of March 31, 2026, the company's total assets stood at RMB 6.239 billion, with cash reserves reaching RMB 792 million. Based on the lower limit of RMB 50 million for the repurchase, this amount accounts for only 0.80% of the company's total assets and 1.13% of the net equity attributable to shareholders of the parent company, indicating a relatively minor financial impact overall.

In the share repurchase report, TOPCHOICE MEDICAL stated that this repurchase is based on confidence in the company's future development prospects and recognition of its intrinsic value, aiming to safeguard shareholders' equity. Previously disclosed materials from the 2025 annual shareholders' meeting show that the company achieved a net profit attributable to shareholders of the parent company of RMB 502 million in 2025, and plans to retain profits without distributing dividends for subsequent construction of ophthalmology and oral hospital projects.

Currently, TOPCHOICE MEDICAL's controlling shareholder, actual controller, and directors and senior management personnel have clearly responded that they have no plans to reduce their holdings in the next three or six months. The repurchase period is set at 12 months from the date of approval by the 2025 annual shareholders' meeting.